Thanks to President Biden and Democrats in Congress, Medicare can finally negotiate lower drug prices

Now, big drug companies are suing to stop negotiations and protect their massive profits

Keep up with the Medicare drug price negotiation process

What is the Medicare price negotiation program?

In 2022, Democrats won a decades-long battle against Big Drug Companies to finally allow Medicare to negotiate lower prescription drug prices. The new program created by the Inflation Reduction Act will lower costs for some of the highest-priced prescription drugs on the market used to treat conditions like cancer, diabetes, and autoimmune disorders – conditions that disproportionately impact women, communities of color, and people in rural areas.

In August of 2023, the Biden administration announced the first ten prescription drugs eligible for Medicare negotiation. Those negotiations will culminate in the publication of maximum fair prices for those drugs on September 1, 2024. Those prices will take effect in 2026, adding another 15 drugs in 2027 and 2028, and another 20 in 2029 and subsequent years.

The first 10 drugs selected for negotiation:

Eliquis for blood clots     Enbrel for arthritis and psoriasis     Entresto for heart failure     Farxiga for diabetes     Fiasp/NovoLog for diabetes      
Eliquis for blood clots     Enbrel for arthritis and psoriasis     Entresto for heart failure     Farxiga for diabetes     Fiasp/NovoLog for diabetes      
Eliquis for blood clots     Enbrel for arthritis and psoriasis     Entresto for heart failure     Farxiga for diabetes     Fiasp/NovoLog for diabetes      
Imbruvica for leukemia and lymphoma     Januvia for diabetes     Jardiance for diabetes     Stelara for Crohn’s disease     Xarelto for blood clots      
Imbruvica for leukemia and lymphoma     Januvia for diabetes     Jardiance for diabetes     Stelara for Crohn’s disease     Xarelto for blood clots      
Imbruvica for leukemia and lymphoma     Januvia for diabetes     Jardiance for diabetes     Stelara for Crohn’s disease     Xarelto for blood clots      
Full list and details
Medicare has spent nearly $174 Billion on the first 10 selected drugs
U.S. drug prices are up to 4x higher than prices in other high-income countries
Negotiations are projected to save Medicare, taxpayers, and seniors $25 Billion annually

How will Medicare negotiating drug prices affect your state?

How Big Drug Companies Are Misleading You To Protect Their Sky-High Profits

#1

Despite long-standing precedent, the drug companies argue that the government shouldn’t regulate them.

#2

Big drug companies think Medicare is constitutionally required to pay whatever prices corporations set.

#3

Big drug companies don’t think they should have to play by the rules and think they should be immune from lawful price regulation.

#4

Big drug companies don’t want Medicare to have a say in setting drug prices.

#5

Big drug companies think Medicare shouldn’t be allowed to attach certain conditions and language to its own funding and programs.

#6

Even though they can opt-out, big drug companies argue they are required to participate in Medicare.

#7

Big drug companies think they shouldn’t have to pay fines for violating their agreements to participate in Medicare and refusing to negotiate drug prices.

“Negotiating drug prices, alongside other provisions of this law, isn’t just going to put more money back in the pockets of millions of Americans across the country. It’s also going to lower the federal deficit.”

Joe BidenPresident of the United States

“Pharma’s sweetheart deal has ended. First list of ten blockbuster drugs eligible for negotiation under Medicare is out and includes blood thinners and diabetes and arthritis drugs that millions and millions of seniors take.”

Amy KlobucharU.S. Senator, Minnesota

Share your drug prices story today

If you or someone you know have been or will be impacted by the Medicare Negotiation process or other health care measures in the Inflation Reduction Act, please take a moment to share your story and join the movement to reduce drug prices and protect access to quality, affordable health care for all Americans.

Share Your Story